Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis.
Chlorpromazine and thioridazine are phenothiazines employed in the treatment of psychosis. These agents inhibited the respiration of clinical isolates of Mycobacterium tuberculosis resistant to streptomycin, rifampin, isoniazid, ethambutol and/or pyrazinamid, all first line drugs. Since any adverse reaction to thioridazine is generally less severe than to chlorpromazine, the possibility is attractive that thioridazine may have a potential in the initial management of patients with newly diagnosed tuberculosis with an as yet undetermined antibiotic susceptibility profile.
Amaral
L
L
Department of Pathology and Clinical Laboratories, Bronx-Lebanon Hospital Center, New York, USA.
Kristiansen
J E
JE
Abebe
L S
LS
Millett
W
W
D014150:Antipsychotic Agents / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology*; D002746:Chlorpromazine / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000378:metabolism*; D010101:Oxygen Consumption / Q000187:drug effects*; D013881:Thioridazine / Q000494:pharmacology*; D014376:Tuberculosis / Q000188:drug therapy
D014150:Antipsychotic Agents; D000995:Antitubercular Agents; D013881:Thioridazine; D002746:Chlorpromazine